In the SURMOUNT program (SM), treatment with tirzepatide led to a significant and clinically meaningful reduction in body weight (BW) in overweight and obese subjects. In a post-hoc analysis, the effect of tirzepatide treatment on body weight in women was examined according to the stage of menopause.
Autoren
- Jens Dehn
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- MASLD/MASH
Drug therapy options on the rise: spectacular evidence
- New ways of neuroregeneration
CRISPR and artificial intelligence
- Asbestos victims
Federal Council has decided to amend the UVG
- Music as a cure for cancer?
Music therapy in Swiss oncology
- Clinical significance, pathophysiology, diagnosis and management
Frailty in COPD
- Bladder infections and urinary tract infections
Survey reveals information deficits in the population
- Early detection of type 1 diabetes
Detection of insulin autoantibodies as an early marker
- Type 2 diabetes